🔎 Trials Near Me

Home › Scleroderma › Maryland › Baltimore

Pag-aaral pangklinika para sa Scleroderma sa Baltimore, MD

6 pag-aaral para sa Scleroderma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Baltimore (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

Nagre-recruitPhase 2
  • Johns Hopkins Asthma and Allergy Center, Baltimore
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06655155

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Nagre-recruitPhase 1
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT03816345

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

Nagre-recruitPhase 3
  • Johns Hopkins Hospital, Baltimore
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07497087

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Nagre-recruitPhase 1
  • Johns Hopkins Hospital, Baltimore
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Set 10, 2026 · NCT07085104

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Nagre-recruitPhase 2/3
  • GSK Investigational Site, Baltimore
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT05878717

Platform Clinical Study for Conquering Scleroderma

Nagre-recruitPhase 2
  • Johns Hopkins University School of Medicine, Baltimore
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT06195072

Pag-aaral para sa Scleroderma sa ibang lungsod

Iba pang pag-aaral sa Baltimore

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.